417 results match your criteria: "Institut Universitaire du Cancer Toulouse-Oncopole[Affiliation]"
Neuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFBr J Haematol
December 2024
Division of Hematology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Acute myeloid leukaemia (AML) arising from a myeloproliferative neoplasm (MPN) is more aggressive and less responsive to therapies compared to de novo AML. Olutasidenib, an oral small-molecule inhibitor of mutated IDH1 (mIDH1), showed encouraging and durable responses in a phase 1/2 study of adults with post-MPN mIDH1 AML. Patients received olutasidenib 150 mg BID monotherapy or in combination with azacitidine.
View Article and Find Full Text PDFBMJ Open
November 2024
Subaquatic and Hyperbaric Medicine Unit, Emergency Service, Acute Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Introduction: Sickle cell disease (SCD) is one of the most common genetic diseases in the world, annually affecting approximately 310 000 births and causing >100 000 deaths. Vaso-occlusive crisis (VOC) is the most frequent complication of SCD, leading to bone pain, thoracic pain (acute chest syndrome) and/or abdominal spasms. It is the main cause of mortality in patients with SCD, reducing life expectancy.
View Article and Find Full Text PDFInt J Gynecol Cancer
December 2024
Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Rev Med Interne
November 2024
Service de médecine interne, centre de référence maladies auto-immunes et auto-inflammatoires systémiques rares d'Île-de-France, de l'Est et de l'Ouest, hôpital Cochin, université Paris-Cité, AP-HP, Paris, France; Inserm UMRS 1138, centre de recherche des cordeliers, université Paris-Cité, Paris, France.
Br Dent J
November 2024
Professor of Cariology & Operative Dentistry and Honorary Consultant, Restorative Dentistry, Faculty of Dentistry, Oral & Craniofacial Sciences, King´s College London, UK; Honorary Consultant Advisor, Office of the Chief Dental Officer, England, UK.
Given the prevalence of head and neck carcinoma and the salivary changes induced by the oral side effects of radiotherapy, such patients are at higher risk/susceptibility of developing dental caries. Radiation-caries is often under-treated in patients undergoing cervicofacial radiotherapy, yet these lesions can increase the risk of osteoradionecrosis due to necessary subsequent dental extractions. Moreover, xerostomia is accompanied by difficulties with speech, chewing and swallowing.
View Article and Find Full Text PDFWorld J Urol
November 2024
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
J Cancer Educ
October 2024
Département d'Odontologie, Université Paul Sabatier, Service d'Odontologie, Centre Hospitalier Universitaire, Laboratoire Centre d'Anthropobiologie Et de Génomique de Toulouse, 3 Chemin Des Maraîchers, 31400, Toulouse, France.
After resection of malignant tumors of the head and neck, reconstructions are commonly performed using surgical free flaps. In non-irradiated patients, hair may continue to grow at the reconstruction site after surgery, causing undesirable effects such as difficult to maintain oral hygiene, food and saliva accumulation, halitosis, dysphagia, moral distress, and impact on intimacy and sexuality. Until a standardized laser therapy protocol is available, manual depilation is an option that should not be underestimated to improve the patient's quality of life and available to every oral healthcare team.
View Article and Find Full Text PDFBr J Cancer
November 2024
Adolescents and Young Adults Unit, Medical Oncology and SIREDO (Care, Innovation and Research for Children, Adolescents, and Young Adults with Cancer) Departments, Curie Institute, Paris, France.
J Eur Acad Dermatol Venereol
September 2024
Department of Dermatology, Nantes Université, CHU Nantes, Nantes, France.
Eur Urol Open Sci
October 2024
Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Background And Objective: More than 10% of patients with negative clinical metastatic status (cN0M0) on conventional imaging for prostate cancer (PCa) harbor lymph node involvement (pN+) at final pathology following radical prostatectomy (RP) and lymphadenectomy. Our aim was to assess outcomes of initial observation for cN0M0 pN+ PCa and identify prognostic factors that may help in clinical decision-making.
Methods: We performed a retrospective multicenter study of patients with cN0M0 PCa on conventional imaging (computed tomography and/or magnetic resonance imaging, and a bone scan) who were found to have pN+ disease at RP between 2000 and 2021.
Int J Gynecol Cancer
October 2024
Department of Obstetrics and Gynecology, Houston Methodist Hospital, Neal Cancer Center, Houston, Texas, USA.
In March 2024, 12 European Network of Young Gynae Oncologists- (ENYGO-IJGC) Editorial Fellows conducted 10 interviews with senior opinion leaders on original and controversial topics in the field of gynecologic oncology presented during the 25th European Society of Gynaecological Oncology (ESGO) Congress in Barcelona, Spain. This article provides a summary and overview of the content of these discussions summarizing key points presented at the meeting. These selected interviews were chosen by consensus by the ENYGO-IJGC Editorial Fellows based on novelty and relevance to the field of gynecologic oncology.
View Article and Find Full Text PDFInt J Gynecol Cancer
August 2024
Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
Oral Dis
August 2024
Department of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
J Dent Educ
August 2024
Department of Dental surgery, Université Paul Sabatier, Centre Hospitalier Universitaire, Toulouse, France.
Rev Med Interne
November 2024
Service de médecine interne, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares d'Île de France, de l'Est et de l'Ouest, hôpital Cochin, AP-HP, université Paris-Cité, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address:
Rationale: On the occasion of the General stage meeting of Internal Medicine, the National College of Internal Medicine Teachers (CEMI) conducted a survey on teaching activity among all French university hospital (HU) internal medicine specialists.
Method: The survey was carried out in September 2023 by sending an email to 101 hospital practitioners university professors (PU-PH) and 18 hospital practitioners assistant professors (MCU-PH) of internal medicine in subsection 53-01 of the National council of universities (CNU), as well as to the 11 HU internists working in immunology (subsection 47-01) or therapeutics (subsection 48-04).
Results: Seventy-three HUs (56.
Br Dent J
July 2024
Département de Médecine Orale, Oncopole Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, Toulouse, France.
Background: Cervical cancer's lymphatic spread primarily begins from the sentinel lymph nodes (SLNs), underlining their pivotal role in disease metastasis. However, these nodes' immune gene expression profiles and immunoregulation mechanisms have yet to be explored.
Methods: Our study aimed to elucidate the immune cell populations and their roles in the immune gene expression profile of negative SLNs compared with positive SLNs and non-SLNs using Nanostring RNA seq analysis.
J Pathol
August 2024
CRCT, Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.
The E3 ubiquitin ligase thyroid hormone receptor interacting protein 12 (TRIP12) has been implicated in pancreatic adenocarcinoma (PDAC) through its role in mediating the degradation of pancreas transcription factor 1a (PTF1a). PTF1a is a transcription factor essential for the acinar differentiation state that is notably diminished during the early steps of pancreatic carcinogenesis. Despite these findings, the direct involvement of TRIP12 in the onset of pancreatic cancer has yet to be established.
View Article and Find Full Text PDFItal J Dermatol Venerol
October 2024
Department of Oncodermatology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Eur Urol Oncol
December 2024
Biopathologie et Génétique des Cancers, Institut Médical d'Analyse Génomique, Imagenome, Inovie, Montpellier, France; Unité de Recherche Clinique, Clinique Beausoleil, Montpellier, France. Electronic address:
Background And Objective: Metastatic prostate cancer (mPCa) harbors genomic alterations that may predict targeted therapy efficacy. These alterations can be identified not only in tissue but also directly in biologic fluids (ie, liquid biopsies), mainly blood. Liquid biopsies may represent a safer and less invasive alternative for monitoring patients treated for mPCa.
View Article and Find Full Text PDFLancet Oncol
June 2024
University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Background: The KEYNOTE-057 trial evaluated activity and safety of pembrolizumab in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. In cohort A (patients with carcinoma in situ, with or without papillary tumours) of the KEYNOTE-057 study, pembrolizumab monotherapy led to a complete response rate of 41% at 3 months, and 46% of responders maintained a response lasting at least 12 months. Here, we evaluate pembrolizumab monotherapy in cohort B of patients with papillary tumours without carcinoma in situ.
View Article and Find Full Text PDFHaematologica
September 2024
Hématologie FBeirorlaongdiq, uFer,a nCcHe U Clermont-Ferrand, Clermont; Equipe d'Accueil EA7453 CHELTER, Université Clermont Auvergne, Clermont-Ferrand, France; Hématologie Clinique Adulte, CHU Clermont-Ferrand, Clermont-Ferrand.
Ann Dermatol Venereol
June 2024
Department of Oncodermatology, Institut Universitaire du Cancer - Toulouse Oncopole, Toulouse, France. Electronic address: